Overcoming Challenges of Biotherapeutics with Recombumin

Recombumin®: An Adaptable Stabilizer for Complex Drug and Vaccine Formulations

  • Defends against surface adsorption allowing for lasting liquid formulations and an enhanced dosage control
  • Leads to reformulation, from lyophilized to uncomplicated liquid formulations, without undermining durability
  • Minimizes undesirable immunogenicity by the reduction of aggregation and oxidation
  • Possibility to bring valuable yet initially unstable drug candidates to market
  • Commercially certified in marketed products

Overcoming Formulation Challenges of Biotherapeutics

The increasing study of vaccines and biotherapeutics gives promise for improvement of treatments against various diseases. While protein engineering has shown a great level of growth, several of these therapies persist in the face of ex vivo uncertainty challenges (both physical and chemical instability) which are a source of dosage form inadequacy, and undesirable immunogenic responses.

Recombumin® Elite and Recombumin® Prime by Albumedix supplies drug formulators with a flexible and competent stabilizer when operating with difficult to formulate drug candidates for example biotherapeutics of a high concentration, drugs that are highly potent and unpredictable therapeutic peptides.

By putting into play several characteristics of Recombumin®, drug developers can conquer these fundamental formulation issues.

About Albumedix Ltd.Albumedix Ltd.

Too many people battle with diseases that keep them from living a full life. Healthcare professionals work hard every day to provide these people with better therapies. Together with partners, Albumedix utilize its albumin-based drug enhancing products and technologies to enable the development of more effective treatments.

With more than 30 years of experience, we are proud to be recognized as the world leader in recombinant human albumin products and technologies.

As the highest quality recombinant human albumin products ever developed, Albumedix enables the effective formulation of otherwise hard-to-stabilize drugs, cell therapies, and vaccines.

Our albumin-based technologies offer new ways of optimizing drug dosing and enhancing therapeutic performance by increasing the half-life, payload capacity, and tissue specific delivery of active pharmaceutical agents. This results in simpler treatment regimens, better performance, and, ultimately, improved patient outcomes.

Albumedix is headquartered in Nottingham, UK, with both research and large-scale manufacturing facilities. We are all committed to improving patient quality of life and are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Sep 25, 2020 at 9:56 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Albumedix Ltd.. (2020, September 25). Overcoming Challenges of Biotherapeutics with Recombumin. News-Medical. Retrieved on March 03, 2021 from https://www.news-medical.net/whitepaper/20190117/Overcoming-Challenges-of-Biotheraputics-with-Recombumin.aspx.

  • MLA

    Albumedix Ltd.. "Overcoming Challenges of Biotherapeutics with Recombumin". News-Medical. 03 March 2021. <https://www.news-medical.net/whitepaper/20190117/Overcoming-Challenges-of-Biotheraputics-with-Recombumin.aspx>.

  • Chicago

    Albumedix Ltd.. "Overcoming Challenges of Biotherapeutics with Recombumin". News-Medical. https://www.news-medical.net/whitepaper/20190117/Overcoming-Challenges-of-Biotheraputics-with-Recombumin.aspx. (accessed March 03, 2021).

  • Harvard

    Albumedix Ltd.. 2020. Overcoming Challenges of Biotherapeutics with Recombumin. News-Medical, viewed 03 March 2021, https://www.news-medical.net/whitepaper/20190117/Overcoming-Challenges-of-Biotheraputics-with-Recombumin.aspx.

Other White Papers by this Supplier